Impact of Lung Function and COPD on the Prevalence and Mortality of CKM Syndrome: Evidence from a Cross-Sectional Study.

IF 2.8 4区医学 Q3 RESPIRATORY SYSTEM

COPD: Journal of Chronic Obstructive Pulmonary Disease Pub Date : 2025-12-01 Epub Date: 2025-11-04 DOI:10.1080/15412555.2025.2582809

Jisong Yan, Xingyao Tang, Minghui Shi, Wei Li, Tingting Huang, Yanan Cui, Yaodie Peng, Rui Su, Ting Yang, Ke Huang

{"title":"Impact of Lung Function and COPD on the Prevalence and Mortality of CKM Syndrome: Evidence from a Cross-Sectional Study.","authors":"Jisong Yan, Xingyao Tang, Minghui Shi, Wei Li, Tingting Huang, Yanan Cui, Yaodie Peng, Rui Su, Ting Yang, Ke Huang","doi":"10.1080/15412555.2025.2582809","DOIUrl":null,"url":null,"abstract":"Background: Chronic obstructive pulmonary disease (COPD) and cardiovascular-kidney-metabolic (CKM) syndrome are major public health concerns, yet their interrelationship remains under-explored. This study investigates the impact of lung function and COPD on the prevalence and mortality of CKM syndrome using data from the National Health and Nutrition Examination Survey (NHANES) 2007-2012.Methods: A cross-sectional analysis of 5569 adults was conducted, defining CKM stages per the 2023 American Heart Association framework. Lung function was assessed via prebronchodilator spirometry, with COPD classified using GOLD criteria. Advanced CKM syndrome (stages 3-4) was the primary outcome. Associations were evaluated using survey-weighted logistic regression, restricted cubic splines (RCS), and cox proportional hazards models.Results: Among participants, 10.7% had advanced CKM syndrome. COPD was significantly associated with advanced CKM(adjusted OR = 1.52 [1.11, 2.09]), with escalating risks across GOLD stages (GOLD stage II: OR = 2.13 [1.21, 3.74]; GOLD stage III-IV: OR = 4.38 [1.06, 18.02]). Pre-COPD conditions, including preserved ratio impaired spirometry (PRISm) (OR = 2.62 [1.66, 4.14]) and chronic bronchitis (OR = 2.60 [1.50, 4.53]), also showed significant associations. COPD increased all-cause mortality (HR = 1.40 [1.04, 1.89]) and cardiovascular-related mortality (HR = 1.81 [1.04, 3.14]) in individuals aged ≥50 with advanced CKM.Conclusion: COPD is strongly associated with advanced CKM syndrome and increased mortality. These findings highlight the systemic impact of lung health on CKM progression and outcomes, emphasizing the need for integrated screening and management strategies targeting both pulmonary and cardiometabolic health, especially in older adults.","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"22 1","pages":"2582809"},"PeriodicalIF":2.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"COPD: Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15412555.2025.2582809","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chronic obstructive pulmonary disease (COPD) and cardiovascular-kidney-metabolic (CKM) syndrome are major public health concerns, yet their interrelationship remains under-explored. This study investigates the impact of lung function and COPD on the prevalence and mortality of CKM syndrome using data from the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

Methods: A cross-sectional analysis of 5569 adults was conducted, defining CKM stages per the 2023 American Heart Association framework. Lung function was assessed via prebronchodilator spirometry, with COPD classified using GOLD criteria. Advanced CKM syndrome (stages 3-4) was the primary outcome. Associations were evaluated using survey-weighted logistic regression, restricted cubic splines (RCS), and cox proportional hazards models.

Results: Among participants, 10.7% had advanced CKM syndrome. COPD was significantly associated with advanced CKM(adjusted OR = 1.52 [1.11, 2.09]), with escalating risks across GOLD stages (GOLD stage II: OR = 2.13 [1.21, 3.74]; GOLD stage III-IV: OR = 4.38 [1.06, 18.02]). Pre-COPD conditions, including preserved ratio impaired spirometry (PRISm) (OR = 2.62 [1.66, 4.14]) and chronic bronchitis (OR = 2.60 [1.50, 4.53]), also showed significant associations. COPD increased all-cause mortality (HR = 1.40 [1.04, 1.89]) and cardiovascular-related mortality (HR = 1.81 [1.04, 3.14]) in individuals aged ≥50 with advanced CKM.

Conclusion: COPD is strongly associated with advanced CKM syndrome and increased mortality. These findings highlight the systemic impact of lung health on CKM progression and outcomes, emphasizing the need for integrated screening and management strategies targeting both pulmonary and cardiometabolic health, especially in older adults.

查看原文本刊更多论文

肺功能和COPD对CKM综合征患病率和死亡率的影响：来自横断面研究的证据。

背景：慢性阻塞性肺疾病（COPD）和心血管肾代谢综合征（CKM）是主要的公共卫生问题，但它们之间的相互关系仍未得到充分探讨。本研究利用2007-2012年国家健康与营养调查（NHANES）的数据，调查了肺功能和COPD对CKM综合征患病率和死亡率的影响。方法：对5569名成年人进行横断面分析，根据2023年美国心脏协会框架定义CKM分期。通过支气管扩张剂前肺活量测定法评估肺功能，使用GOLD标准对COPD进行分类。晚期CKM综合征（3-4期）是主要结局。使用调查加权logistic回归、限制性三次样条（RCS）和cox比例风险模型评估相关性。结果：在参与者中，10.7%患有晚期CKM综合征。COPD与晚期CKM显著相关（调整后的OR = 1.52 [1.11, 2.09]）， GOLD分期的风险逐渐升高（GOLD II期：OR = 2.13 [1.21, 3.74]； GOLD III-IV期：OR = 4.38[1.06, 18.02]）。copd前疾病，包括保存比例受损肺活量（PRISm）（OR = 2.62[1.66, 4.14]）和慢性支气管炎（OR = 2.60[1.50, 4.53]）也显示出显著的相关性。在年龄≥50岁的晚期CKM患者中，COPD增加了全因死亡率（HR = 1.40[1.04, 1.89]）和心血管相关死亡率（HR = 1.81[1.04, 3.14]）。结论：COPD与晚期CKM综合征和死亡率增高密切相关。这些发现强调了肺部健康对CKM进展和结局的系统性影响，强调了针对肺部和心脏代谢健康的综合筛查和管理策略的必要性，特别是在老年人中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

COPD: Journal of Chronic Obstructive Pulmonary Disease RESPIRATORY SYSTEM-

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： From pathophysiology and cell biology to pharmacology and psychosocial impact, COPD: Journal Of Chronic Obstructive Pulmonary Disease publishes a wide range of original research, reviews, case studies, and conference proceedings to promote advances in the pathophysiology, diagnosis, management, and control of lung and airway disease and inflammation - providing a unique forum for the discussion, design, and evaluation of more efficient and effective strategies in patient care.